A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday ...
Zacks.com on MSN1d
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...
GlobalData on MSN2d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...
BMJ1d
Gilead’s anti-diversion clause for lenacapavir exploits vulnerable communities
Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...
GlobalData on MSN4d
Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
FierceBiotech6d
Gilead buys HIV vaccine from Spanish biotech following success in clinical collab
Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...
devdiscourse4h
Breakthrough HIV Prevention Shot Faces Global Access Challenges
The twice-yearly HIV prevention shot from Gilead Sciences has proven 100% effective in women and nearly as effective in men, ...
bovnews1d
What Factors Have Led to Gilead Sciences, Inc. (GILD) Stock Trading -6.56% Below Its 52-Week High?
On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...
Gilead Sciences: Designing Inclusive Clinical Trials In An Effort To Upend The HIV Epidemic
Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...
Zacks Research Lifts Earnings Estimates for Gilead Sciences
Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...